Cuijpers CJJ, van ’t Hooft J, Schneeberger C, et al. - In the present study, the researchers sought to assess the long‐term outcomes after antenatal vaginal progesterone vs placebo (follow‐up of the Triple P trial) in children born to women with a short cervix, and otherwise low‐risk. The Triple P trial randomized low risk women (n = 80) with a short cervix at screening (≤ 30 mm), to progesterone (n = 41) or placebo (n = 39). At 2'years corrected age children were asked for a neurodevelopmental assessment utilizing the Bayley Scales of Infant and Toddler Development‐third edition (BSID‐III) and a neurological and physical examination by a blinded assessor. One child in the progesterone group and 2 children in the placebo group died in the neonatal period of the 80 children born to the randomised women. In this sample of children born to low risk women with a short cervix at screening, no significant variations between those exposed to vaginal progesterone or placebo in neurodevelopmental, behavioural, healthcare related and physical outcomes were identified in the offspring.